Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + Sonrotoclax in R/R Waldenström Macroglobulinemia
NCT06547866Phase 2Not yet recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of sonrotoclax in Waldenström macroglobulinemia (WM), sponsored by French Innovative Leukemia Organisation. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sonrotoclax
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT06547866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547866.